Second Zolgensma Data Snafu For Novartis Not Such A Big Deal
Seeking Alpha,
Novartis had another embarrassing data snafu with Zolgensma last week, where researchers failed to include critical preclinical…
Oooooh, That’s Scary! Welcome to the Dark Side of Biopharma
Biospace,
We all love a good campfire story regarding ghosts, ghouls and things that go bump in the night.
New Biogen Spinraza Trial Has Little To Do With Novartis Competition
Seeking Alpha,
Biogen is initiating a new Phase III trial for Spinraza in adult-onset SMA. The new trial will be testing higher doses to see…
Biogen's ALS Treatment Is Exciting, But Market Is Microscopic
Seeking Alpha,
Summary Biogen and Ionis just reported exciting data on a potential treatment for ALS, and are moving to Phase III.